Cabot Corporation

CBT trades at a 12.98 P/E with RSI at 61.4—neither stretched nor oversold territory. The 7.59% short interest is notable but not extreme for a specialty chemicals play. What stands out is the valuation: at just 12.98x earnings within the broader chemicals sector, there's implicit skepticism about growth prospects, yet the stock sits modestly above its 52-week lows rather than hitting them. This suggests the market has already priced in meaningful caution. The moderate RSI leaves room for either consolidation or pullback, while the short position remains manageable enough that any positive catalyst wouldn't trigger severe squeeze dynamics. The setup feels like a value trap waiting for conviction—either earnings surprise or sector tailwinds to justify the discount